Sonal Bhatia, MD is the Vice President, Medical Affairs, and North America Lead for Rare Disease at Pfizer. In this role, Sonal leads US and Canada Medical Affairs, including Field-based Medical colleagues and is responsible for the development and execution of regional medical strategies in alignment with both Global Medical and the Regional President. Sonal is also responsible for preparing the health care market place (Physicians, Payers & Providers) for the launch of new Rare Disease medicines across US and Canada. Sonal is an active speaker nationally and internationally, where she shared her thoughts around how patient centricity and Real World Evidence (RWE) can effectively usher in a new era for Medical Affairs. Her most recent speaking engagements include Keynote Speaker at World Congress Summit and Medical Affairs Leaders Forum.
Prior to her current role, Sonal was a Senior Medical Director, Team Lead at Pfizer, serving as the Global Medical Affairs Lead for market-leading novel anticoagulant, Eliquis®. She was responsible for all regions to ensure successful execution of the Global Medical Affairs strategy. In that role, she led data generation and communication strategy, leveraging the Real World Evidence, across multiple countries and customers as a complimentary strategy to ongoing clinical development plans.
Sonal graduated from University of Toronto, Canada with a dual major in Cell & Molecular Biology and Spanish Studies and after attaining her medical degree, she completed her residency in Internal Medicine from the Mount Sinai School of Medicine in New York. She has supported brands in various therapeutic areas including Infectious Diseases, Cardiovascular, Metabolic Disease and Ophthalmology. Sonal is an active member of the Healthcare Businesswomen’s Association (HBA), American Diabetes Association (ADA), Pfizer’s Asian and Pacific American Group and Women’s Leadership Network.
Sonal was born in Mexico City and currently lives in New York City with her husband and two children, Isabella & Nicholas.